Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

FDA Approves Durvalumab With FLOT for Resectable Gastric-GEJ Adenocarcinoma

AI Simplifies Patients Comprehension of CT Reports But Are Errors Possible

External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer

No Overall Survival Benefit for Lenvatinib in LEAP-014 Trial of Esophageal Cancer

ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer